Last reviewed · How we verify
GRISEOFULVIN (GRISEOFULVIN, MICROSIZE)
GRISEOFULVIN (generic name: GRISEOFULVIN, MICROSIZE) is a Tubulin Inhibiting Agent [EPC] drug developed by COSETTE. It is currently FDA-approved for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis.
At a glance
| Generic name | GRISEOFULVIN, MICROSIZE |
|---|---|
| Sponsor | COSETTE |
| Drug class | Tubulin Inhibiting Agent [EPC] |
| Target | Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
- Onychomycosis due to dermatophyte
- Tinea barbae
- Tinea capitis
- Tinea corporis
- Tinea cruris
- Tinea pedis
Common side effects
- Skin rashes
- Urticaria
- Nausea
- Vomiting
- Epigastric distress
- Diarrhea
- Headache
- Fatigue
- Dizziness
- Insomnia
- Mental confusion
- Impairment of performance of routine activities
Serious adverse events
- Severe skin adverse events
- Severe hepatic adverse events
- Hepatitis
- Nephrosis
- Proteinuria
- Leukopenia
- Granulocytopenia
- Coagulopathy
- Elevated liver enzymes
- Hyperbilirubinemia
Key clinical trials
- A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin (Phase 1)
- A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Femal (Phase 1)
- Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (Phase 3)
- Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (Phase 3)
- An Open Label, Randomized, Balanced, Three Treatment, Three Period, Three Sequence, Single Dose, Crossover Study to Evaluate the Bioequivalence of Test Griseofulvin Tablets, 500 mg Versus Reference Gr (Phase 1)
- A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Femal (Phase 1)
- A Randomized, Double-Blinded, Placebo-Controlled Study Observing the Efficacy of Selenium Sulfide 1% Shampoo, Ketoconazole 2% Shampoo, and Ciclopirox 1% Shampoo as Adjunctive Treatments for Tinea Capi (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRISEOFULVIN CI brief — competitive landscape report
- GRISEOFULVIN updates RSS · CI watch RSS
- COSETTE portfolio CI
Frequently asked questions about GRISEOFULVIN
What is GRISEOFULVIN?
GRISEOFULVIN (GRISEOFULVIN, MICROSIZE) is a Tubulin Inhibiting Agent [EPC] drug developed by COSETTE, indicated for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis.
What is GRISEOFULVIN used for?
GRISEOFULVIN is indicated for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis, Tinea corporis, Tinea cruris.
Who makes GRISEOFULVIN?
GRISEOFULVIN is developed and marketed by COSETTE (see full COSETTE pipeline at /company/cosette).
What is the generic name of GRISEOFULVIN?
GRISEOFULVIN, MICROSIZE is the generic (nonproprietary) name of GRISEOFULVIN.
What drug class is GRISEOFULVIN in?
GRISEOFULVIN belongs to the Tubulin Inhibiting Agent [EPC] class. See all Tubulin Inhibiting Agent [EPC] drugs at /class/tubulin-inhibiting-agent-epc.
What development phase is GRISEOFULVIN in?
GRISEOFULVIN is FDA-approved (marketed).
What are the side effects of GRISEOFULVIN?
Common side effects of GRISEOFULVIN include Skin rashes, Urticaria, Nausea, Vomiting, Epigastric distress, Diarrhea. Serious adverse events: Severe skin adverse events, Severe hepatic adverse events, Hepatitis, Nephrosis.
What does GRISEOFULVIN target?
GRISEOFULVIN targets Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin and is a Tubulin Inhibiting Agent [EPC].
Related
- Drug class: All Tubulin Inhibiting Agent [EPC] drugs
- Target: All drugs targeting Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
- Manufacturer: COSETTE — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Onychomycosis due to dermatophyte
- Indication: Drugs for Tinea barbae
- Indication: Drugs for Tinea capitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing